SEC Filings
BioNTech Agrees To Pay $205 Million To Shorten A Future Cancer Drug's FDA Review
The voucher would cover one application from its late-stage oncology pipeline, while Comirnaty remains its one marketed product.
BioNTech (BNTX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The voucher would cover one application from its late-stage oncology pipeline, while Comirnaty remains its one marketed product.
Earnings
Talks continue on a tie-up with the co-founders' new venture, but CFO Ramon Zapata said it is not a necessity.
SEC Filings
A 541-patient late-stage trial showed a modest progression-free survival gain, with more lung disease than in earlier studies of the drug.
SEC Filings
Gilead will supply Trodelvy for the ROSETTA Breast-01 study, though the change awaits approval from regulators.
SEC Filings
The trial continues toward an overall survival analysis that, under its design, could still make the outcome positive.